Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines
Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines
复制标题
DOI：
10.1016/j.vaccine.2003.12.011
复制
发表时间：
2004-06-30
期刊：
影响因子：
5.5
通讯作者：
Montefiori, DC
中科院分区：
文献类型：
--
作者：
Evans, TG;Frey, S;Montefiori, DC
人类免疫缺陷病毒I型（HIV-1）疫苗的有效性和实际应用可能部分取决于所产生的免疫应答的寿命，特别是记忆舱中的免疫应答。基于HIV-1包膜糖蛋白的候选疫苗在人体内产生结合和中和抗体，但之前没有关于这些反应的长期持久性和回忆的研究。我们评估了6名健康的、未感染HIV的成年人，他们接受了gp 120增强的重组金丝雀痘HIV-1疫苗的组合，并获得了HIV-1 MN中和抗体的高血清滴度。这些人在最后一次接种疫苗后4-5年接受了gp 160加强免疫。4名志愿者在加强免疫时具有可检测的结合和中和抗体，所有6名志愿者均表现出回忆结合和中和抗体应答。这些抗体中和了多种T细胞系适应（TCLA）病毒株，包括疫苗株，但不包括原代分离株。这些结果表明，记忆B细胞反应可以持续多年后，HIV-1包膜糖蛋白免疫。原则上，类似的长期记忆可能与改进的免疫原产生广泛的交叉反应性中和抗体。(C)2004爱思唯尔有限公司保留所有权利。
The efficacy and practical application of human immunodeficiency virus type I (HIV-1) vaccines may depend in part on the longevity of the immune responses generated, particularly those in the memory compartment. Candidate vaccines based on the HIV-1 envelope glycoproteins generate binding and neutralizing antibodies in humans but there have been no prior studies on the long-term persistence and recall of those responses. We evaluated six healthy, HIV non-infected adults who had received a combination of recombinant canarypox HIV-1 vaccines boosted by gp120 and who had achieved a high serum titer of neutralizing antibody to HIV-1 MN. These individuals were administered a gp160 boost 4-5 years after their last vaccination. Four volunteers had detectable binding and neutralizing antibodies at the time of boosting and all six volunteers exhibited a recall binding and neutralizing antibody response. The antibodies neutralized multiple T cell line-adapted (TCLA) strains of virus, including the vaccine strain, but not primary isolates. These results demonstrate that memory B-cell responses can last for many years following HIV-1 envelope glycoprotein immunization. In principle, similar long-term memory may be possible with improved immunogens that generate broadly cross-reactive neutralizing antibodies. (C) 2004 Elsevier Ltd. All rights reserved.